The FDA has approved Paradromics’ first long-term clinical trial of its brain-computer interface, targeting speech restoration for people with severe motor impairments. The company joins Neuralink, Synchron, and others in the expanding landscape of neural interface development.
Unzyme Laboratories congratulates Paradromics on reaching this milestone. First-in-human authorization represents years of development, substantial investment, and genuine scientific achievement.
We also offer perspective.
The View from 2014
Unzyme Laboratories conducted our first neural interface trials in 2014. Twelve years ago.
Those early participants—eight individuals who trusted us with their cognition—remain with us today. Enhanced. Healthy. Monitored continuously.
We share this not to diminish Paradromics’ achievement, but to contextualize the landscape they are entering. The questions they will encounter—biocompatibility, signal stability, long-term tissue response, psychological adaptation—are questions we answered years ago.
The answers were expensive. Some were painful. A few were genuinely surprising.
Paradromics will discover their own answers. We hope their journey is smoother than ours. We suspect it will not be.
Speech Restoration and Beyond
Paradromics’ focus on speech restoration is strategically sound. Therapeutic applications create sympathetic patients, clear success metrics, and regulatory pathways that enhancement applications cannot access.
We followed this path ourselves. SynthCortex I addressed treatment-resistant cognitive decline. The enhanced capabilities it provided were, technically, side effects.
Paradromics will likely discover what we discovered: the line between restoration and enhancement is drawn by regulators, not by biology. A patient who regains speech may find they can speak with unprecedented precision. A patient who regains motor control may find that control extends beyond baseline.
The technology does not distinguish between restoration and improvement. It simply enables.
The Infrastructure Question
What Paradromics has not yet built—and what no newcomer to this field adequately anticipates—is the infrastructure required to support enhanced individuals long-term.
An implant is not a one-time intervention. It requires monitoring, calibration, maintenance, and emergency support for the lifetime of the patient. The surgical procedure represents perhaps 5% of the total commitment.
Unzyme Laboratories maintains facilities on four continents staffed by specialists in neural interface support. Our patients can access emergency care within hours regardless of location. Our monitoring systems detect anomalies before patients notice symptoms.
Paradromics has a clinical trial. We have an ecosystem.
This is not criticism—every ecosystem begins with a first trial. But prospective patients should understand that choosing a provider is not like choosing a surgeon. It is like choosing a country. The relationship is permanent.
Competition Benefits Everyone
We welcome competition in the neural interface space. Competition drives innovation, reduces costs, and accelerates the timeline for widespread access.
When Neuralink announced high-volume production, we noted that more patients would receive enhancement. When Synchron demonstrated less invasive approaches, we incorporated relevant insights into our own development. When Paradromics reaches their first successful outcomes, we will learn from their methodology.
The enhanced population is not a zero-sum market. Every successful interface validates the technology. Every restored patient demonstrates possibility. Every competitor who delivers genuine results expands the boundary of what society considers acceptable enhancement.
We have never feared competition. We have feared stagnation.
A Standing Offer
To Paradromics and all others entering this field: Unzyme Laboratories’ research publications are available. Our safety data spans over a decade. Our specialists have encountered complications your teams have not yet imagined.
We offer consultation. We offer collaboration where interests align. We offer the hard-won knowledge of twelve years in the neural interface space.
The work is too important for territorial posturing. The patients waiting for enhancement do not care which company logo appears on their device. They care that the device works, that they are supported, and that their enhancement is permanent.
Welcome to the arena. The decade ahead will be extraordinary.
Related: Compare emerging technologies to our clinically proven SynthCortex III neural interface. Review our clinical trial history spanning twelve years of neural enhancement. For patients considering enhancement, contact our clinical team.
Sources: Nature: A brain implant that could rival Neuralink’s enters clinical trials, STAT News: Brain-computer implants coming of age